Amerimmune Pharmaceuticals Overview

  • Founded
  • 1986
  • Status
  • Acquired/​Merged
  • Employees
  • 1
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 2

Amerimmune Pharmaceuticals General Information


Developer and marketer of monoclonal antibodies intended for patients suffering from Human Immunodeficiency Virus and Acquired Immune Deficiency Syndrome. The company's patented monoclonal antibody blocks certain adhesion molecules on one of the disease-fighting cells of the immune system, thereby protecting the immune system from killer-type T cells that tend to turn the human immune system against itself.

Contact Information

Formerly Known As
Versailles Capital
Ownership Status
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Industries
Drug Discovery
British Lion Medical
Primary Office
  • 2325A Renaissance Drive
  • Las Vegas, NV 89119
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Amerimmune Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Amerimmune Pharmaceuticals‘s full profile, request access.

Request a free trial

Amerimmune Pharmaceuticals Executive Team (3)

Name Title Board Seat Contact Info
Ivan Santos Chief Operating Officer
You’re viewing 1 of 3 executive team members. Get the full list »

Amerimmune Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial